fda glp-1 warning letters news Sends 30 To Continue Clampdown on Compounded GLP-1s FDA takes aim at telehealth

Kidney Protection and Brain Health A trial found semaglutide reduced kidney events by 24% in people with type 2 diabetes and chronic kidney disease using a lower dose, not the maximum. GLP-1s also strengthen the blood-brain barrier and enhance neuron survival, with early data hinting at benefits for cognitive decline and Alzheimer's disease. Systemic Anti-Inflammatory Effects GLP-1s reduce systemic inflammation throughout the body. This benefit doesn't get talked about much, though inflammation drives almost every chronic disease

And evidence suggests stopping the drugs seems to reverse many of those health benefits as well

Regenerons Phase 2 COURAGE trial echoed these results in humans: combination therapy significantly reduced fat while preserving up to 81% of lean mass loss compared to semaglutide alone

The best course of action with any GLP-1 treatment is to continue your treatment plan for as long as possible to ensure you get maximum benefits

the latter requires immediate medical assessment

Some don't notice any change at all